Abstract: A coat hanger assembly includes a housing and a hanger body. The hanger body is displaceable between a stowed position within the housing and a use position projecting from the housing. The hanger body includes a stem and two arms pivotally mounted to the stem. The two arms are displaceable between a home position and a deployed position. When fully erected the coat hanger allows one to easily hang a coat or other clothing article. A related method of hanging a clothing article is also disclosed.

Abstract: The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: A rechargeable power system comprising: a drill string configured to operate in a well bore, the drill string comprising: a fuel cell system; a generator in electrical communication with the fuel cell system; a turbine, configured to rotate due to an impingement of drilling mud on one or more turbine blades, the turbine in operable communication with the generator; and where the fuel cell system is configured to provide power at least when drilling mud is not circulating in the well bore, and further configured to be recharged by the generator when drilling mud is circulating in the well bore. A method for operating a rechargeable downhole fuel cell. The method comprises: monitoring a fluid supply pressure; determining whether the fluid supply pressure is below a threshold value; and stopping a fuel cell discharge if the fluid supply pressure is below the threshold value.

Abstract: A vehicle having a cargo area accessible through a lift gate opening frame and partially defined by a floor and side quarter panels is provided. The vehicle includes guide tracks supported by the side quarter panels and a tray movable between a stowed position adjacent the floor and at least one deployed position. First and second pegs extend from opposing sides of the tray and engage the guide tracks. Similarly, first and second retention pins extend from the opposing sides of the tray and engage first and second receivers supported by the side quarter panels in the at least one deployed position. A handle is supported by the tray. A release mechanism may be connected to the retention pins and is used to retract the pins from the receivers.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A cargo area for a vehicle includes a load floor, a package tray, and a pair of cargo area side walls each comprising a package tray translating element including a vehicle-forward facing guide surface for translating the package tray between at least one deployed position at a spaced distance above the load floor and a stowed position on the load floor. Vehicle-forward upper and lower indents are disposed at spaced intervals along the vehicle-forward facing guide surface. A cooperating package tray retaining element includes vehicle-rearward upper and lower indents disposed on the cargo area side walls. A vehicle-forward edge of the package tray includes a follower element adapted for translating the package tray between the at least one deployed position and the stowed position. A vehicle-rearward edge of the package tray includes a retractable retaining element adapted to releasably and selectively engage the vehicle-rearward upper and lower indents.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt or solvate thereof, wherein A and A? are C or N, where C may be substituted by halo or C1-C6 alkyl; R and R0 are selected from the group consisting of H, C1-C6 alkyl, —(CH2)n—W, etc., where W is 5- or 6-membered heteroaryl or heterocyclic containing N, S and/or O atoms, —NR?SO2—R?, etc., where R? and R? are C1-C6 alkyl, etc.; wherein each alkyl, etc., may be substituted; or, R and Ro and the N atom to which they are bonded together to form a monocyclic or bicyclic heterocyclic ring, etc.; R1 is H, halo or cyano; R2 and R2? are H, C1-C6 alkyl, etc.; X is a bond, etc.; R3 is H, C1-C4 alkyl, etc.; Y is a bond, —(CH2)m—, etc. The invention also relates to compositions and uses in the treatment of various diseases.

Abstract: The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjôgren's Syndrome, and other CFTR associated disorders.

Abstract: A spectroscopic device, which may be a handheld spectroscopic light source, which uses ambient light as a primary broadband light source, but which may be supplemented with an auxiliary light source to supplement band regions which may be deficient in the broad band source. The spectroscopic device makes use of a number of parallel control channels to monitor for sufficient light and to compensate for variations in the input light levels.

Abstract: A cargo area for a vehicle includes a load floor, a package tray, and a pair of cargo area side walls each comprising a package tray translating element including a vehicle-forward facing guide surface for translating the package tray between at least one deployed position at a spaced distance above the load floor and a stowed position on the load floor. Vehicle-forward upper and lower indents are disposed at spaced intervals along the vehicle-forward facing guide surface. A cooperating package tray retaining element includes vehicle-rearward upper and lower indents disposed on the cargo area side walls. A vehicle-forward edge of the package tray includes a follower element adapted for translating the package tray between the at least one deployed position and the stowed position. A vehicle-rearward edge of the package tray includes a retractable retaining element adapted to releasably and selectively engage the vehicle-rearward upper and lower indents.

Abstract: Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention relates to compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.

Abstract: A confidence value is determined for data collected for a lane assist subsystem in a vehicle. A section curvature is identified for a section of a roadway when the confidence value is below a confidence value, threshold. The section curvature includes at least one section start point and at least one section end point. The section curvature is based at least in part on a heading angle, the heading angle defining an angle between a projected line of travel of the vehicle and a line segment from a vehicle position to the section end point. A distance to a lane boundary is predicted based at least in part on the identified section curvature. One or more vehicle subsystems is actuated based at least in part on the predicted distance to the lane boundary.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A vehicle having a cargo area accessible through a lift gate opening frame and partially defined by a floor and side quarter panels is provided. The vehicle includes guide tracks supported by the side quarter panels and a tray movable between a stowed position adjacent the floor and at least one deployed position. First and second pegs extend from opposing sides of the tray and engage the guide tracks. Similarly, first and second retention pins extend from the opposing sides of the tray and engage first and second receivers supported by the side quarter panels in the at least one deployed position. A handle is supported by the tray. A release mechanism may be connected to the retention pins and is used to retract the pins from the receivers.

Abstract: Embodiments of the present disclosure include a camera carrying and mounting system. The system may include a camera plate configured to mount onto a camera and a coupling mechanism. The camera plate may include a first end, a second end, and a mounting hole configured to receive a fastening element to mount the camera plate to the camera, and the mounting hole may be positioned between the first end and the second end of the camera plate. The coupling mechanism may be coupled to the first end of the camera plate and configured to releasably engage a carrying structure to the camera plate, and the coupling mechanism may include a loop through which the carrying structure extends.

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.